šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX Ā· Real-Time Price Ā· USD
5.08
-0.14 (-2.68%)
At close: Nov 20, 2026, 4:00 PM EST
5.10
+0.02 (0.39%)
After-hours: Nov 20, 2026, 7:30 PM EST

AN2 Therapeutics Earnings Call Transcripts

Fiscal Year 2026

  • Three Phase II programs in PV, M. abscessus and Chagas are expected to generate proof-of-concept data in 2027, led by PV safety and efficacy updates. Earlier research includes oral ENPP1 programs in hypophosphatasia and oncology.

  • The PV study will test dose response and hematocrit control, with initial readouts planned from Q1 2027. Three phase II programs are expected to report in 2027, while $80 million in cash was projected to fund execution into 2029.

  • PV and Chagas Phase II programs are advancing toward data in 2027, while M. abscessus targets a major oral-treatment gap. A pan-mutant PI3K program remains in research, with development work extending into 2027.

  • Three phase II programs—PV, Mycobacterium abscessus, and Chagas disease—are advancing, with key data readouts expected from late this year through next. Novel oral therapies address significant unmet needs, and additional oncology assets are in early development.

  • The company is leveraging its boron chemistry platform to expand from infectious diseases into oncology and hematology, with epetraborole advancing into phase II for PV and NTM. Multiple near-term catalysts are expected across a diversified pipeline, including solid tumor and Chagas programs.

  • Epetraborole is advancing to Phase 2 for polycythemia vera, with dosing set for August and initial data expected in Q4. The oral agent aims to provide stable hematocrit control and may offer disease-modifying potential. Additional pipeline programs include trials for M. abscessus and Chagas disease.

  • Status update

    Epetraborole is being advanced into phase II trials for PV, targeting a large unmet need for oral, red cell-specific therapies. The drug has shown consistent hematocrit control with minimal off-target effects, and initial clinical data are expected in Q4, with further updates through 2027.

Fiscal Year 2025

  • A major strategic pivot followed a phase III readout in NTM lung disease, with expanded focus on oncology and infectious diseases. Lead oncology and Chagas programs show strong preclinical and early clinical data, with multiple milestones expected in 2026.

  • The pipeline features novel boron-based drugs for infectious diseases and oncology, with strong preclinical and early clinical results in Chagas disease and melioidosis, and a strategic pivot in NTM to target abscessus. Oncology programs target ENPP1 and PI3Kα with best-in-class ambitions.

  • Epetraborole is advancing for severe, refractory NTM lung disease, with phase III data expected in Q2. The primary endpoint is now QOL-B respiratory demand, aligning with FDA guidance, and the drug has shown clinical benefit and good tolerability. The pipeline includes Chagas disease and oncology programs, with cash runway through 2027.

  • The company leverages boron chemistry for a diverse pipeline in infectious diseases and oncology, with key milestones ahead including phase III data for NTM lung disease and phase II starts for Chagas and melioidosis. Cash runway extends through 2027, supporting ongoing development.

  • The company highlighted progress in its boron chemistry platform, with positive Phase II results for epetraborole in NTM lung disease and a robust pipeline including Chagas and melioidosis programs. Regulatory engagement and new clinical data are expected soon.